GlassScriptPhysician profile
Melanie M Anello
NPI 1225336696
$4,844.10
in general payments reported to CMS, 2019-2025
19 companies · $1,516 in 2025
The $1,516 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $728 · 2023: $744 · 2024: $1,857 · 2025: $1,516.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,089 · Education: $27.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,088.82 |
| Education | $27.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,297.31 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $719.78 | 2022-2025 | Entyvio, Eohilia |
| Lilly USA, LLC | $698.12 | 2024-2025 | Omvoh |
| Janssen Biotech, INC. | $492.77 | 2022-2025 | Stelara, Tremfya, Remicade |
| Madrigal Pharmaceuticals | $261.94 | 2024-2025 | Rezdiffra, Resmetirom |
| Aimmune Therapeutics, INC. | $188.77 | 2024-2025 | Vowst |
| Ferring Pharmaceuticals INC. | $177.92 | 2023-2025 | Rebyota |
| Qol Medical, LLC | $167.53 | 2023-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.42 | 2022-2025 | Xifaxan |
| Grifols USA, LLC | $122.31 | 2023 | Prolastin-C Liquid |
| Astrazeneca Pharmaceuticals LP | $121.84 | 2025 | Airsupra |
| Braintree Laboratories, INC. | $115.47 | 2023-2025 | Suflave, Sutab |
| Organon LLC | $87.05 | 2024-2025 | Hadlima |
| Gilead Sciences, INC. | $60.33 | 2024 | |
| Ardelyx, INC. | $56.31 | 2023-2024 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.89 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $45.16 | 2023 | Ocaliva |
| Olympus America INC. | $25.48 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.70 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melanie Anello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.